NIH VideoCast - The Protean Manifestations of GATA2 Deficiency Across the Lifespan

Skip Navigation

The Protean Manifestations of GATA2 Deficiency Across the Lifespan

Loading... Loading video...

395 Views

Air date:	Wednesday, December 11, 2013, 3:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 395 (98 Live, 297 On-demand)
Category:	WALS - Wednesday Afternoon Lectures
Runtime:	01:07:23
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	The NIH Director's Wednesday Afternoon Lecture Series The Annual G. Burroughs Mider Lecture GATA binding factor 2 (GATA2) was initially cloned (1991) as a critical regulator of murine endothelial development, the complete absence of which was incompatible with life. Subsequent work confirmed that it was also critical for hematopoiesis, erythropoiesis, and macrophage function. After almost 20 years of characterization of patients with disseminated mycobacterial infections who had monocytopenia, B cell and NK (natural killer) cell cytopenia, Steve Holland’s group found heterozygous mutations in the same transcription factor, GATA2, accounting for their disease. However, in humans these heterozygous mutations cause haploinsufficiency and underlie myelodysplasia, myeloid leukemia, pulmonary alveolar proteinosis, classical NK cell deficiency, and lymphedema. GATA2 deficiency causes a late onset congenital immunodeficiency that can be cured by bone marrow transplantation. GATA2 is involved in many processes with virtually complete penetrance but highly variable expression, suggesting that genetic and epigenetic modifiers are important. For more information go to http://wals.od.nih.gov

NLM Title:	The protean manifestations of GATA2 deficiency across the lifespan / Steven Holland.
Author:	Holland, Steven M. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): The NIH Director's Wednesday Afternoon Lecture Series The Annual G. Burroughs Mider Lecture GATA binding factor 2 (GATA2) was initially cloned (1991) as a critical regulator of murine endothelial development, the complete absence of which was incompatible with life. Subsequent work confirmed that it was also critical for hematopoiesis, erythropoiesis, and macrophage function. After almost 20 years of characterization of patients with disseminated mycobacterial infections who had monocytopenia, B cell and NK (natural killer) cell cytopenia, Steve Holland"s group found heterozygous mutations in the same transcription factor, GATA2, accounting for their disease. However, in humans these heterozygous mutations cause haploinsufficiency and underlie myelodysplasia, myeloid leukemia, pulmonary alveolar proteinosis, classical NK cell deficiency, and lymphedema. GATA2 deficiency causes a late onset congenital immunodeficiency that can be cured by bone marrow transplantation. GATA2 is involved in many processes with virtually complete penetrance but highly variable expression, suggesting that genetic and epigenetic modifiers are important.
Subjects:	GATA2 Transcription Factor Immunologic Deficiency Syndromes--genetics
Publication Types:	Lecture Webcast

NLM Classification:	WD 308
NLM ID:	101622777
CIT Live ID:	13421
Permanent link:	https://videocast.nih.gov/watch=13421

Related Videos...